Biocytogen partner NEOK Bio gets FDA nod for novel cancer therapy
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Subscribe To Our Newsletter & Stay Updated